Clinical data
Trade names Celontin
AHFS/ Consumer Drug Information
MedlinePlus a682028
  • US: C (Risk not ruled out)
Routes of
By mouth (capsules)
ATC code N03AD03 (WHO)
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic (demethylation and glucuronidation)
Metabolites N-desmethylmethosuximide
Biological half-life 1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
Excretion Urine
CAS Number 77-41-8 YesY
PubChem (CID) 6476
DrugBank DB05246 N
ChemSpider 6231 YesY
UNII 0G76K8X6C0 YesY
KEGG D00404 YesY
ECHA InfoCard 100.000.934
Chemical and physical data
Formula C12H13NO2
Molar mass 203.237 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.[2]


  1. Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
  2. 1 2 Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
  3. Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.
This article is issued from Wikipedia - version of the 9/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.